Dengyong Zhang | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Prof. Dengyong Zhang | Cancer Cell Biology | Best Researcher Award

Prof. Dengyong Zhang , The First Affiliated Hospital of Bengbu Medical university , China

Zhang Deng Yong is a highly accomplished medical professional and researcher specializing in hepatocellular carcinoma and cholangiocarcinoma. Born in Liu’an, Anhui Province, China, in 1989, he currently works as an attending doctor at the First Affiliated Hospital of Bengbu Medical College. Dr. Zhang earned his Bachelor’s and Master’s degrees from Bengbu Medical College and is currently pursuing a Doctor’s degree at Anhui Medical University. He is also a visiting scholar at MD Anderson Cancer Center. With an extensive portfolio of research, Dr. Zhang is known for his significant contributions to the study of cancer biology, particularly in liver and biliary cancers. His commitment to medical research and patient care positions him as a key figure in the field of oncology.

Publication Profile:

Scopus

Strengths for the Award:

Dr. Zhang Deng Yong exhibits exceptional skills and commitment to the field of medical research, particularly in oncology. His advanced academic qualifications (Doctor’s degree from Anhui Medical University and a Master’s degree from Bengbu Medical College) provide a solid foundation for his innovative research. He has made significant contributions to understanding the molecular mechanisms underlying various cancers, especially hepatocellular carcinoma and cholangiocarcinoma, as evidenced by his numerous impactful publications. His collaborative work, demonstrated through his visiting scholar position at the MD Anderson Cancer Center, speaks to his ability to engage in high-caliber research environments.

Areas for Improvement:

While Dr. Zhang’s research portfolio is robust, expanding his involvement in interdisciplinary research or establishing collaborations beyond oncology could open new avenues in cancer treatment and prevention. Additionally, enhancing his focus on translational medicine could bridge the gap between laboratory research and clinical application.

Education:

Dr. Zhang Deng Yong’s academic journey began at Bengbu Medical College, where he earned his Bachelor’s degree in Medicine (2007-2012). He furthered his education with a Master’s degree in Surgery from the same institution (2012-2015). Currently, he is pursuing a Doctor’s degree at Anhui Medical University (2021-2024), specializing in oncology and cancer treatment. His dedication to academic excellence is reflected in his continued involvement in both teaching and advanced clinical research. In addition to his formal education, Dr. Zhang has participated in various international conferences and academic collaborations, further strengthening his expertise in medical research and surgery.

Experience:

Dr. Zhang has a solid background in clinical practice and research. Since 2016, he has served as an attending doctor at the First Affiliated Hospital of Bengbu Medical College, where he specializes in oncology and surgery. He also worked as a resident at Lu’an Traditional Chinese Medicine Hospital from 2015 to 2016. In 2022, Dr. Zhang had the opportunity to enhance his research experience as a visiting scholar at MD Anderson Cancer Center, a leading institution in cancer research. His clinical experience, combined with his academic training, allows him to offer patients the highest standard of care while contributing to groundbreaking cancer research. His expertise in hepatocellular carcinoma and cholangiocarcinoma has made him a sought-after expert in his field.

Awards and Honors:

Dr. Zhang Deng Yong’s commitment to research and medicine has earned him various recognitions and funding opportunities. He was awarded a Natural Science Fund of Anhui Province support from 2018 to 2020. Additionally, his work has been widely recognized in the academic community, where he has acted as a reviewer for multiple prestigious journals such as Oncology Reports, Molecular Medicine Reports, Oncology Letters, and Experimental and Therapeutic Medicine. These roles reflect his standing in the medical and scientific community. His involvement in clinical and research innovation has placed him at the forefront of oncology research, especially in the areas of hepatocellular carcinoma and cholangiocarcinoma.

Research Focus:

Dr. Zhang’s research primarily focuses on cancer biology, particularly hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). He is dedicated to understanding the molecular mechanisms behind cancer progression, immune responses, and therapeutic resistance. His work includes investigating the roles of various genetic and epigenetic factors in the development of liver and biliary cancers, as well as identifying potential biomarkers for early diagnosis and prognosis. Dr. Zhang’s research extends to exploring novel therapeutic approaches, including immunotherapy, targeted therapies, and the use of CRISPR technology. His publications also delve into the immune landscape and molecular pathways that influence cancer progression, with an emphasis on improving patient outcomes through precision medicine. His passion for cancer research and patient care continues to drive his work and innovations in the field.

Publications Top Notes:

  1. Immunosenescence and immunotherapy in elderly patients with hepatocellular carcinoma 🧬🦠

  2. USP1 promotes cholangiocarcinoma progression by deubiquitinating PARP1 to prevent its proteasomal degradation 🧬⚡

  3. CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon 🔬🧬

  4. MiR-186-5p prevents hepatocellular carcinoma progression by targeting methyltransferase-like 3 that regulates m6A-mediated stabilization of follistatin-like 5 💡🧬

  5. The COL7A1/PI3K/AKT axis regulates the progression of cholangiocarcinoma 🔬🧬

  6. Integrative analysis of bulk and single-cell transcriptomic data reveals novel insights into lipid metabolism and prognostic factors in hepatocellular carcinoma 🧬💡

  7. HSDL2 knockdown promotes the progression of cholangiocarcinoma by inhibiting ferroptosis through the P53/SLC7A11 axis ⚡🔬

  8. Application of mesohepatectomy with caudate lobectomy for the treatment of type III–IV hilar cholangiocarcinoma: a single-center retrospective study 🏥📑

  9. Prognostic model for hepatocellular carcinoma based on anoikis-related genes: immune landscape analysis and prediction of drug sensitivity 🔬💉

  10. Bile metabolites as diagnostic biomarkers for perihilar cholangiocarcinoma 🧬💡

Conclusion:

Dr. Zhang Deng Yong’s expertise in cancer research, particularly his contributions to hepatocellular carcinoma and cholangiocarcinoma, places him as a strong contender for the Research for Best Researcher Award. His dedication to advancing medical knowledge, coupled with his impressive list of publications and international collaboration, makes him an invaluable asset to the scientific community. With continued growth in clinical application, Dr. Zhang is poised for further recognition and impactful contributions to medical research.

 

 

 

Li Hou | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Prof. Li Hou | Cancer Cell Biology | Best Researcher Award

Prof. Li Hou , Department of Oncology and Hematology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China

Li Hou is a distinguished Chief Physician and Director of the Hematology and Oncology Department at Dongzhimen Hospital, affiliated with Beijing University of Chinese Medicine. With a career spanning over 30 years, she has made remarkable contributions in the integration of Traditional Chinese Medicine (TCM) and Western Medicine for treating tumors and blood diseases. A renowned researcher and educator, Hou Li has led over 40 research projects, authored 50+ papers, and published significant work on tumor and blood disease therapies. Her expertise has been recognized with the prestigious “Famous Doctor’s Excellent Demeanor Award” in 2018. Her passion for advancing healthcare through combined approaches has made her a leader in oncology and hematology in China and internationally. 🌟🎓💉

Publication Profile:

Orcid

Strengths for the Award:

Dr. Li Hou is highly deserving of the Best Researcher Award due to her exceptional contributions in integrating Traditional Chinese Medicine (TCM) and Western Medicine for the treatment of hematological diseases and cancers. Her career is distinguished by over 40 research programs and more than 50 published papers, demonstrating her expertise in oncology and hematology. She has authored notable articles in high-impact journals, showcasing her deep understanding of tumor biology and blood disorders. Her leadership in research, coupled with her clinical practice, has led to groundbreaking insights into the treatment of malignancies, including her work on identifying novel drug targets for cancers. Furthermore, her role in academia and professional service, as a key figure in several influential medical associations, highlights her outstanding impact in the medical field. 🌟🧑‍🔬📚

Areas for Improvement:

While Dr. Li Hou research achievements are commendable, expanding her research collaborations internationally could further enhance her impact. Engaging with global research communities may foster new perspectives and facilitate the exchange of ideas, particularly in the context of cutting-edge medical technologies. Additionally, expanding research into the long-term outcomes of integrated therapies in various populations could provide further evidence of the benefits of combining TCM with Western approaches. This would allow her work to gain even more recognition and clinical application worldwide. 🌍🔬

Education:

Li Hou completed her Bachelor’s in Chinese Medicine at Beijing University of Chinese Medicine in 1993. She then pursued her Master’s degree in Integrated Chinese and Western Medicine from the same institution, completing it in 1998. In 2004, she earned her Doctorate in Integrated Chinese and Western Medicine. Her academic journey has been rooted in the application of both traditional and modern methods to treat complex diseases like cancer and blood disorders, providing her with a strong foundation for her career in clinical practice, research, and education. 🎓📚🩺

Experience:

Li Hou clinical career began in 1993 as a resident at Dongzhimen Hospital. By 1999, she advanced to attending physician, and by 2008, she became an associate chief physician. In 2013, she was appointed as Chief Physician at Dongzhimen Hospital, where she has been working ever since. She holds significant leadership roles within the field, including Chairman of several prestigious oncology committees. Additionally, her role as an evaluation expert for the National Natural Science Foundation of China demonstrates her expertise in research. She has been instrumental in combining traditional Chinese medicine with modern treatments in the management of cancer and hematological conditions. 🏥💼👩‍⚕️

Research Focus:

Li Hou research focus revolves around the integration of Traditional Chinese Medicine (TCM) and Western medicine to treat hematological diseases and cancer. She has made significant strides in identifying novel therapeutic approaches, with an emphasis on improving cancer treatment outcomes. Her work includes studying the role of TCM in modulating drug responses and enhancing chemotherapy effectiveness. Through her extensive research, she has contributed to understanding the genetic and molecular mechanisms involved in blood cancer and tumor progression, aiming to optimize patient care and survival rates. Her studies have been published in leading medical journals. 🧬🔬💡

Publications Top Notes:

  • Identification of potential drug targets for four site-specific cancers by integrating human plasma proteome with genome – Journal of Pharmaceutical and Biomedical Analysis (2025)
  • Genetic analysis from multiple cohorts implies causality between 2200 druggable genes, telomere length, and leukemia – Computers in Biology and Medicine (2024)
  • Genetically predicted 486 blood metabolites in relation to risk of colorectal cancer: A Mendelian randomization study – Cancer Medicine (2023)
  • Improvement of Early Death in Acute Promyelocytic Leukemia: A Population-Based Analysis – Clinical Lymphoma Myeloma and Leukemia (2023)
  • Tanshinone IIa Induces Autophagy and Apoptosis via PI3K/Akt/mTOR Axis in Acute Promyelocytic Leukemia NB4 Cells – Evidence-Based Complementary and Alternative Medicine (2021)
  • Effectiveness of Acupuncture Treatment on Chemotherapy-Induced Peripheral Neuropathy: A Pilot, Randomized, Assessor-Blinded, Controlled Trial – Pain Research and Management (2020) 📝📚🎯

Conclusion:

Dr. Li Hou contributions to medicine are profound and multifaceted, blending traditional and modern therapeutic approaches to offer innovative solutions for cancer and blood diseases. Her research has not only advanced scientific knowledge but also improved patient care. As a leader in both clinical practice and research, she exemplifies the qualities of a Best Researcher Award recipient. Through her continued dedication to her work, Dr. Hou Li will undoubtedly remain at the forefront of medical research, driving progress in both China and globally. 🏆💉🩺

 

 

 

 

Huining He | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Prof. Huining He | Cancer Cell Biology | Best Researcher Award

Prof. Huining He , School of Biomedical Engineering and Technology, Tianjin Medical University , China

Dr. Huining He is a prominent Professor and the Dean of the School of Biomedical Engineering and Technology at Tianjin Medical University, China. With a Ph.D. in Chemical Engineering from Tianjin University, she completed joint research at the University of Michigan. Her career spans across significant achievements in biomedical engineering, specializing in biomaterials, drug delivery systems, and cancer therapy. She has been recognized with prestigious awards, including the “Young Changjiang Scholar” and the “Tianjin Science Fund for Outstanding Young Scholars.” As an active member of various academic societies and a board member of the Asian Journal of Pharmaceutical Sciences, she fosters international collaboration and academic advancement. Her research has garnered substantial contributions to the field of biomedical engineering, with numerous patents and high-impact publications in cancer treatment and drug delivery systems.

Publication Profile:

Scopus

Strengths for the Award:

Dr. Huining He is an outstanding researcher with a strong academic and professional background. As a Professor and Dean at Tianjin Medical University, she leads the School of Biomedical Engineering and Technology with a focus on cutting-edge biomedical research, particularly in biomaterials and drug delivery systems. Her innovative work in the development of enzyme-sensitive targeted systems for gene therapy and prodrug-type macromolecular drug delivery for colon cancer is a key contribution to the field. Additionally, her leadership in several projects funded by the National Natural Science Foundation of China, particularly those targeting glioma treatment, showcases her ability to translate research into impactful clinical applications.

Dr. He’s collaboration with international and domestic institutions further enhances her research impact. She is well-regarded for pioneering novel drug delivery systems and has made notable contributions through numerous high-quality publications, which have earned her an H-index of 21 and six authorized patents. She also actively participates in academic exchanges and professional networks, serving as a member of editorial boards and scientific committees.

Areas for Improvements:

While Dr. He has made remarkable strides in biomedical engineering, there are areas where further focus could amplify her impact:

  1. Broader Clinical Application: The continued translation of her drug delivery systems into clinical settings could benefit from additional industry partnerships and clinical trials.
  2. Interdisciplinary Collaboration: Expanding her work to incorporate emerging fields such as artificial intelligence in drug delivery systems could lead to more personalized treatment solutions.
  3. Public Engagement: Increasing public awareness of her research through media and outreach could bridge the gap between academia and the general public, facilitating broader societal impact.

Education:

Dr. Huining He earned her Ph.D. in Chemical Engineering from Tianjin University, where she gained profound expertise in biomaterials and drug delivery systems. During her doctoral studies, she participated in joint training at the University of Michigan, an experience that greatly expanded her research skills and international perspective. This training allowed her to engage in cutting-edge projects in the fields of biomaterials and drug delivery. Her advanced education laid the foundation for her future contributions to biomedical engineering, especially in the development of novel targeted systems for gene therapy and cancer treatment. Dr. He’s academic journey has been marked by strong mentorship, international collaborations, and her leadership role in several research projects that have significantly advanced the biomedical field.

Experience:

Dr. Huining He’s career in biomedical engineering spans extensive academic and research experience. Currently, as the Dean of the School of Biomedical Engineering and Technology at Tianjin Medical University, she leads a dynamic department focused on advancing healthcare solutions through innovative research. She has supervised numerous Ph.D. students, guiding them in pioneering research on biomaterials and drug delivery systems. Her work has been recognized by the Ministry of Education, with prestigious titles such as the “Young Changjiang Scholar.” Dr. He has led and contributed to several high-profile research projects funded by China’s National Natural Science Foundation, including investigations into enzyme-sensitive targeted systems for gene therapy and glioma treatment. Beyond academia, she has participated in industry projects, translating her research into real-world applications. As a member of numerous professional organizations and editorial boards, Dr. He plays a vital role in facilitating international collaborations and advancing scientific knowledge in the biomedical sector.

Research Focus:

Dr. Huining He’s research focuses on the design and development of advanced biomaterials and drug delivery systems, particularly in the treatment of cancer and other serious diseases. Her work involves creating innovative, targeted drug delivery systems that can enhance the efficacy and precision of treatment. She has conducted pivotal studies on enzyme-sensitive targeted systems for gene therapy, improving the delivery of therapeutic agents to cancer cells. Currently, Dr. He is leading several projects on siRNA co-delivery systems for glioma, investigating ways to overcome the challenges in glioma treatment. Her research also covers the development of prodrug-type macromolecular systems and multifunctional exosome-based drug delivery technologies. Dr. He’s work has the potential to revolutionize cancer treatment and other therapeutic approaches, contributing to the development of more efficient, less toxic therapies for patients. Her research continues to make substantial advancements in the fields of drug delivery, biomedical engineering, and cancer therapy.

Publications Top Notes:

  1. CaCO3-based nanomedicine with multi-functions of ferroptosis-apoptosis and microenvironment regulation in cancer 🔬💡 (Nano Today, 2025)
  2. Lipid Nanoparticular Codelivery System for Enhanced Antitumor Effects by Ferroptosis-Apoptosis Synergistic with Programmed Cell Death-Ligand 1 Downregulation 🧬⚡ (ACS Nano, 2024)
  3. Nanomedicine integrating the lipidic derivative of 5-fluorouracil, miriplatin and PD-L1 siRNA for enhancing tumor therapy 💊🧪 (Chinese Chemical Letters, 2024)
  4. A review on gold nanoparticles as an innovative therapeutic cue in bone tissue engineering: Prospects and future clinical applications 🏥🔬 (Materials Today Bio, 2024)
  5. Lipid core-shell nanoparticles co-deliver FOLFOX regimen and siPD-L1 for synergistic targeted cancer treatment 🧬🔗 (Journal of Controlled Release, 2024)
  6. An injectable signal-amplifying device elicits a specific immune response against malignant glioblastoma 💉🧠 (Acta Pharmaceutica Sinica B, 2023)
  7. Antitumor synergism between PAK4 silencing and immunogenic phototherapy of engineered extracellular vesicles 🧬💥 (Acta Pharmaceutica Sinica B, 2023)
  8. Dual-sensitive drug-loaded hydrogel system for local inhibition of post-surgical glioma recurrence 💧⚔ (Journal of Controlled Release, 2022)
  9. Antibody–siRNA conjugates (ARC): Emerging siRNA drug formulation 🧬💉 (Medicine in Drug Discovery, 2022)
  10. mRNA vaccines for COVID-19 and diverse diseases 💉🦠 (Journal of Controlled Release, 2022)

Conclusion:

Dr. Huining He’s exceptional contributions to the field of biomedical engineering, particularly in the development of novel drug delivery systems for cancer treatment, position her as an ideal candidate for the Best Researcher Award. Her innovative work, combined with a clear vision for the future of precision medicine, continues to drive the field forward. She has the potential to further revolutionize medical treatments, making her a deserving nominee for this prestigious recognition.